组织型纤溶酶原激活剂挽救治疗重症COVID-19相关急性呼吸窘迫综合征:病例系列
本文报告5例因COVID-19相关呼吸衰竭、常规治疗难以奏效而接受组织型纤溶酶原激活剂(tPA;阿替普酶)纤溶治疗的病例。所有5例在给药后均出现呼吸状态改善:1例初期明显改善但数小时后部分回落,1例改善短暂未维持,3例出现持续临床改善。作者据此认为tPA可能改善此类患者的呼吸状态。证据等级为治疗性、Level V。
要点
- 5例常规治疗难以奏效的COVID-19相关呼吸衰竭患者接受阿替普酶纤溶治疗。
- 给药后5例呼吸状态均有改善:3例持续改善,1例初期明显改善后部分回落,1例短暂改善未维持。
- 作者认为tPA可能改善COVID-19相关重症呼吸衰竭患者的呼吸状态。
- 证据等级为治疗性、Level V,属病例系列。
适用人群与场景
- 因COVID-19相关呼吸衰竭、常规治疗难以奏效的危重患者。
处置流程与药物剂量
- 使用组织型纤溶酶原激活剂(tPA;阿替普酶)进行纤溶治疗。
研究设计与关键结果
- 病例系列纳入5例常规治疗难以奏效的COVID-19相关呼吸衰竭患者,接受阿替普酶纤溶治疗。
- 给药后5例呼吸状态均有改善:1例初期明显改善、数小时后部分回落;1例短暂改善未维持;3例持续临床改善。
- 证据等级:治疗性,Level V。
证据类型、等级与局限
- 证据类型:病例系列。
- 证据等级:治疗性,Level V。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,对常规治疗难以奏效的COVID-19相关呼吸衰竭患者,使用阿替普酶纤溶可能改善呼吸状态。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
The coronavirus disease 2019 (COVID-19) pandemic has led to unprecedented stresses on modern medical systems, overwhelming the resource infrastructure in numerous countries while presenting a unique series of pathophysiologic clinical findings. Thrombotic coagulopathy is common in critically ill patients suffering from COVID-19, with associated high rates of respiratory failure requiring prolonged periods of mechanical ventilation. Here, we report a case series of five patients suffering from profound, medically refractory COVID-19-associated respiratory failure who were treated with fibrinolytic therapy using tissue plasminogen activator (tPA; alteplase). All five patients appeared to have an improved respiratory status following tPA administration: one patient had an initial marked improvement that partially regressed after several hours, one patient had transient improvements that were not sustained, and three patients had sustained clinical improvements following tPA administration. LEVEL OF EVIDENCE: Therapeutic, Level V.
参考来源
- Barrett CD, Oren-Grinberg A, Chao E, et al. Rescue therapy for severe COVID-19-associated acute respiratory distress syndrome with tissue plasminogen activator: A case series. J Trauma Acute Care Surg. 2020. PMID: 32427773. doi:10.1097/TA.0000000000002786
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。